Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID L OLIVER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1164404455
CMS profile
623992
Location
OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$405.23

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $399.33 4
Education $5.90 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Amarin Pharma Inc. $130.01 2
Novo Nordisk Inc $115.56 1
Ironwood Pharmaceuticals, Inc $95.45 1
Amgen Inc. $64.21 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID L OLIVER

NPI 1164404455 · CMS profile ID 623992

Allopathic & Osteopathic Physicians / Family Medicine

OCALA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164404455?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID L OLIVER, NPI 1164404455, CMS profile ID 623992. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164404455?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DAVID L OLIVER, NPI 1164404455, CMS profile ID 623992. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164404455?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DAVID L OLIVER, NPI 1164404455, CMS profile ID 623992, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1164404455?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $405.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amarin Pharma Inc. $5.9009/27/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699227973 CMS
Amarin Pharma Inc. $124.1109/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699218017 CMS
Amgen Inc. $64.2106/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662286613 CMS
Ironwood Pharmaceuticals, Inc $95.4505/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709207267 CMS
Novo Nordisk Inc $115.5602/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703498987 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $405.23 5
PY2020 $282.42 6
PY2021 $509.12 6
PY2022 $770.26 8
PY2023 $290.27 6
PY2024 $2,305.91 23
PY2025 $352.28 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,288,478.03 35
PY2024 Recipient $48,730.50 2
PY2024 Principal investigator $760,191.54 106
PY2023 Recipient $795.01 2
PY2023 Principal investigator $798,688.88 48
PY2022 Recipient $274.00 1
PY2022 Principal investigator $738,187.49 166
PY2021 Principal investigator $437,882.52 38
PY2020 Recipient $193,202.48 6
PY2020 Principal investigator $298,634.23 42
PY2019 Principal investigator $211,648.73 76

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006775621
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006775633
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006775645
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006775659
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006775671
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006775683
Principal investigator 1 Novo Nordisk AS $9.74 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006838129
Principal investigator 1 Novo Nordisk AS $9.74 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006838143
Principal investigator 1 Novo Nordisk AS $9.74 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006838155
Principal investigator 1 Novo Nordisk AS $9.74 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006838167
Principal investigator 1 Novo Nordisk AS $9.74 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007433501
Principal investigator 1 Novo Nordisk AS $9.74 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007433509
Principal investigator 1 Novo Nordisk AS $9.74 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007433517
Principal investigator 1 Novo Nordisk AS $9.74 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007433525
Principal investigator 1 Novo Nordisk AS $9.74 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007433533
Principal investigator 1 Novo Nordisk AS $9.74 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007433541
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007865955
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007865961
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007865969
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007865975
Principal investigator 1 Novo Nordisk AS $9.74 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007865981
Principal investigator 1 Novo Nordisk AS $9.74 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007865987
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007899809
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007899815
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007899821
Principal investigator 1 Novo Nordisk AS $160.00 12/29/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1007899829
Principal investigator 1 Novo Nordisk AS $2,086.11 11/27/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006775609
Principal investigator 1 Novo Nordisk AS $2,800.00 09/22/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006775595
Principal investigator 1 Eli Lilly and Company $391,416.00 07/03/2023 Non-covered Recipient Entity
RENSTAR INC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1038150409
Principal investigator 1 Novo Nordisk AS $629.10 06/23/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006775583
Principal investigator 1 Eli Lilly and Company $72,367.02 06/16/2023 Non-covered Recipient Entity
RENSTAR INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1038123861
Principal investigator 1 Eli Lilly and Company $31,262.00 06/06/2023 Non-covered Recipient Entity
RENSTAR INC
A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 1038136995
Recipient Eli Lilly and Company $600.01 05/21/2023 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1038049431
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 05/18/2023 Non-covered Recipient Entity
Renstar Medcl Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110081
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 05/18/2023 Non-covered Recipient Entity
Renstar Medcl Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110083
Recipient Eli Lilly and Company $195.00 04/28/2023 Covered Recipient Physician A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1038049427
Principal investigator 1 Eli Lilly and Company $1,095.45 04/25/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 1038081163
Principal investigator 1 Eli Lilly and Company $2,834.34 04/19/2023 Non-covered Recipient Entity
RENSTAR INC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1038137005
Principal investigator 1 Eli Lilly and Company $40,897.00 04/04/2023 Non-covered Recipient Entity
RENSTAR INC
RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3857210 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 1038139355
Principal investigator 1 Eli Lilly and Company $46,742.00 04/04/2023 Non-covered Recipient Entity
RENSTAR INC
A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 1038141469
Principal investigator 1 Eli Lilly and Company $2,686.08 03/07/2023 Non-covered Recipient Entity
RENSTAR INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1038126255
Principal investigator 1 Eli Lilly and Company $1,227.93 02/23/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 1038065177
Principal investigator 1 Eli Lilly and Company $1,110.90 02/23/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3857210 FOR THE TREATMENT OF CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 1038065705
Principal investigator 1 Eli Lilly and Company $1,441.80 02/23/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1038130257
Principal investigator 1 Eli Lilly and Company $77,763.00 01/30/2023 Non-covered Recipient Entity
RENSTAR INC
A MASTER PROTOCOL FOR RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALS OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF CHRONIC PAIN No dispute reported 06/30/2026 1038150403
Principal investigator 1 Janssen Research & Development, LLC $9,500.00 01/26/2023 Non-covered Recipient Entity
Renstar Medcl Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 986110079
Principal investigator 1 Novo Nordisk AS $1,543.19 01/25/2023 Non-covered Recipient Entity
RENSTAR MEDICAL RESEARCH
NN9535-4801 No dispute reported 06/30/2026 1006838115
Principal investigator 1 Eli Lilly and Company $106,150.65 01/09/2023 Non-covered Recipient Entity
RENSTAR INC
RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1038139327
Principal investigator 1 Eli Lilly and Company $97.53 01/03/2023 Non-covered Recipient Entity
RENSTAR INC
RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1038126279
Principal investigator 1 Eli Lilly and Company $181.90 01/02/2023 Covered Recipient Teaching Hospital
UNIVERSITY OF ALABAMA HOSPITAL
RANDOMIZED PLACEBO CONTROLLED PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1038065183